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2Abstract
Objectives: To determine the contribution of submicroscopic chromosomal imbalances to 
the etiology of Silver-Russell syndrome (SRS) and SRS like phenotypes. 
Study design: We performed molecular karyotyping in 41 patients with SRS or SRS like 
features without known chromosomes 7 and 11 defects using the Affymetrix SNP Array 6.0 
system. 
Results: In eight patients, pathogenic de-novo copy number variations (CNVs) with sizes 
ranging from 672kb to 9.158 Mb were identified. The deletions in 1q21, 15q26, 17p13 and 
22q11 were associated with known microdeletion syndromes with overlapping features with 
SRS. The duplications in 22q13 and Xq25q27 represent unique novel CNVs, but have an 
obvious influence on the phenotype. In 5 further patients, the pathogenetic relevance of the 
detected variants remained unclear. 
Conclusion: Pathogenic submicroscopic imbalances were detectable in a significant 
proportion of patients with short stature and features reminiscent of SRS. Therefore, 
molecular karyotyping should generally be implemented in routine diagnostics for growth 
retarded patients with even slight dysmorphisms suggestive for SRS.
Key words: Silver-Russell syndrome – molecular karyotyping – submicroscopic 
imbalances – growth retardation – microdeletion/duplication syndromes
3Introduction
Silver-Russell syndrome (SRS; OMIM #180860) patients show  a severe intrauterine and 
postnatal growth restriction (< P3), associated with a variable spectrum of further features. 
Classical SRS includes a relative macrocephaly, a triangular-shaped face with a prominent 
forehead and a small chin, body and limb asymmetry, and fifth finger clinodactyly1. Some 
patients show  a mild motor and cognitive delay (learning difficulties and speech delay). By 
molecular genetic testing, in approximately 50% of  patients with characteristic SRS 
phenotypes, epigenetic and genomic aberrations can be detected: In 7-10% of patients a 
maternal uniparental disomy of  chromosome 7 (upd(7)mat) can be observed, a 
hypomethylation of the imprinting control region 1 (ICR1) in 11p15 is present in more than 
38% of patients. Additionally, cytogenetic aberrations have been reported in single cases, but 
uniform patterns were not apparent1. However, approximately half of patients with SRS still 
remain without molecular diagnosis (“idiopathic”).
As the clinical spectrum of SRS is broad, the diagnosis is challenging and influenced by 
investigator experience. To assist the clinical diagnosis of SRS, Bartholdi et al.2 recently 
developed a detailed scoring system which includes five groups of  clinical measures 
(biometry at birth, postnatal course, asymmetry, facial features, other features). According to 
this system, patients with ICR1 hypomethylation generally show  a more classical SRS 
phenotype than patients with upd(7)mat or patients with idiopathic SRS. This observation 
confirms other studies on (epi)genotype-phenotype correlations in the different molecular 
SRS subgroups3-5. Nevertheless, many exceptions exist6 and molecular testing for SRS 
should thus also be considered in patients with ambiguous phenotypes. 
In the last decade microarray-based genomic copy-number analysis has become a powerful 
tool for the detection of  submicroscopic chromosomal imbalances. Whereas in conventional 
cytogenetic methods the detection of chromosomal aberrations is limited to a resolution of 
5-10 Mb, molecular karyotyping enables the detection of considerably smaller imbalances 
(e.g. 100 kb and less, depending on the used array platform). In patients with MR of 
4unknown etiology the implementation of molecular karyotyping has lead to a more than two-
fold increase in the detection rate of pathogenic chromosomal anomalies compared to 
conventional cytogenetic approaches7,8. Nevertheless, molecular karyotyping is not 
commonly implemented in standard genetic diagnostic procedures for disorders lacking 
mental retardation.
Initial  analyses on idiopathic patients with SRS indicate that pathogenetically relevant 
submicroscopic chromosomal imbalances significantly contribute to the spectrum of 
(epi)mutations9,10. However, the patient cohorts analysed so far were small and the findings 
may be not representative. Moreover, novel array systems with higher resolutions are 
available, potentially resulting in an increased detection rate for cryptic causal aberrations. 
To corroborate the observation that small chromosomal imbalances significantly contribute to 
the etiology of SRS(-like) phenotypes we performed molecular karyotyping in 41 idiopathic 
patients referred as SRS for routine diagnostic testing. 
Material and Methods
Study population
The study population consisted of 41 patients with SRS features (without ICR1 
(epi)mutations and upd(7)mat) and their parents. All patients were initially referred as SRS 
for routine diagnostic testing because they had intrauterine and/or postnatal growth 
retardation and suggestive clinical features. Genomic DNA was isolated from peripheral 
lymphocyte cells by salting-out11. The study was approved by the ethical committee of the 
University Hospital Aachen. Appropriate informed consent was obtained from all participating 
patients or legal representatives.
Clinical scoring system
5For a standardised clinical characterization of  our idiopathic patients with SRS, we applied 
the scoring system recently developed by Bartholdi et al.2 (the “Bartholdi score”) with some 
modifications. In brief, the patients’ symptoms were assigned to five groups: biometric 
measures at birth, postnatal course of  growth, asymmetry, facial features, and other 
features. For the different groups at least three features were scored and 0-3 points were 
given when the signs were present or not. In contrast to Bartholdi et al. we defined a 
maximum score of 14 points because our clinical questionnaire did not include information 
on genital abnormalities. As we could not obtain complete information on all features of some 
patients, we calculated a percentage score instead of an absolute score. Patients with a 
score of ≥53.3 % (≥8/15 points) were classified as typical SRS according to Bartholdi et al.2
Microarray analyses
For the detection of submicroscopic genomic imbalances (<5 Mb) we typed genomic DNA by 
using the Affymetrix GeneChip®Genome-Wide Human SNP 6.0-Array including 1.8M 
oligonucleotide markers. After PCR amplification and labelling of  DNA, the samples were 
hybridized to the arrays according to the manufacturer’s instructions. Scanning was 
performed with an Affymetrix GeneChip®Scanner 3000 7G, bioinformatics was done with the 
Affymetrix Genotyping Console 4.0 and the Chromosome Analysis Suite 1.1 software using 
annotation files version NA30 (hg18/NCBI build 36) and an in-house reference file consisting 
of 90 samples. For analysis and interpretation, only copy number variations (CNVs) >100 kb 
with a mean marker distance <5 kb were considered. To detect uniparental isodisomies the 
samples were checked for regions of homozygosity with a minimal size of 1 Mb.
To determine the inheritance of so far unreported CNVs and to confirm the array results, 
either array analyses of  the parents’ DNA, short tandem repeat (STR) typing or quantitative 
PCR (qPCR) were performed. For qPCR analyses, the Power SYBR® Green PCR Master 
Mix (Applied Biosystems, Weiterstadt, D) in a final reaction volume of 10 µl was used on a 
StepOnePlus real-time PCR instrument (Applied Biosystems, Weiterstadt, D). Information on 
primers used for qPCR and microsatellite typing are listed in Table I (available at 
www.jpeds.com).
6The evaluation of the pathogenic significance of  the detected imbalances was leaned on the 
assessment algorithm suggested by Miller et al.8. Imbalances completely covered by CNVs 
previously identified in healthy controls were regarded as not pathogenic; CNV data were 
obtained from our own control cohort and from several studies using high resolution 
techniques registered in the database of  genomic variants (DGV, http://projects.tcag.ca/
variation/). The remaining CNVs were evaluated in respect to their overlap with common 
microdeletion/microduplication syndromes and gene coverage using the UCSC genome 
browser (http://genome.ucsc.edu/), the OMIM (http://www.ncbi.nlm.nih.gov/omim) and the 
DECIPHER database (https://decipher.sanger.ac.uk/syndromes). The inheritance of these 
CNVs was determined by typing of  parental DNA samples. In case the CNV was inherited 
from an unaffected parent it was classified as a probably apathogenic rare familial variant. 
In patients with obviously pathogenic imbalances, conventional cytogenetic and FISH 
analyses of  the patients and their parents were suggested to the referring laboratories and 
physicians.
Results
We detected an average of 8 common CNVs per patient, which were either registered in the 
DGV database or had been observed in our own control cohort. 
In 24 out of the 41 patients with SRS so far unknown CNVs were detected (Figure 1). Eleven 
of the so far novel CNVs were inherited from an unaffected parent and therefore were more 
likely to represent non-pathogenic changes. This group included a patient with a maternally 
inherited 15q13 microdeletion which has recently been reported as a new  microdeletion 
syndrome with incomplete penetrance12. The 15q13 microdeletion in our patient could also 
be observed in her unaffected mother but not in her growth-retarded half-sister. As the 15q13 
microdeletion syndrome is meanwhile well established and does not include growth 
retardation as a typical sign, we assumed that the 15q13 microdeletion in our family is not 
associated with the phenotype.
7In 8 patients, the identified imbalances were judged to be likely pathogenic because they 
fulfilled at least one of the following criteria (Table II): i) overlap with common microdeletion/
microduplication syndromes associated with growth delay; ii) overlap with CNVs identified in 
further patients with short stature from public and in-house databases; iii) affecting genes 
with a role in regulation of growth and development; iv) cosegregation with growth 
retardation in the family. 
In 5 patients, the pathogenetic relevance of the detected CNVs remained unclear (Table II) 
since they have neither been reported in other growth retarded patients nor contained known 
genes involved in growth and development.
Pathogenic CNVs 
The German patient SR5695 carried a heterozygous 1.65 Mb deletion in 1q21, a region 
which is deleted in patients with distal 1q21-microdeletion syndrome13 (Figure 2,A). The 
deletion affected 14 RefSeq genes. It could be excluded in the mother but paternal DNA was 
not available. The boy was born at term. At the age of  7 8/12 years the boy had short stature. 
Further features suggestive of SRS were a triangular shaped face with a prominent 
forehead, slightly downturned corners of the mouth, retrognathia, clinodactyly V, café-au-lait 
spots and a squeaky voice. Additionally, mitral insufficiency and attention deficit hyperactivity 
disorder (ADHD) were reported. In total, the clinical data in patient SR5695 result in a score 
of 50.0% and are thereby only slightly suggestive for SRS. Interestingly, we identified a 
second patient, SR9116 (Figure 3,A), with nearly the same aberration in 1q21 (Figure 2,A). 
The girl was born at term and showed pre- as well as postnatal growth restriction. Speech 
development was delayed. Craniofacial features included hypertelorism, a broad nasal root 
and large posteriorly rotated ears. Clinodactyly of  digits V and syndactyly of toes II and III 
were present. Several nevi were visible. The total score was 46.2%. The deletion was 
inherited from the unaffected mother (size 162 cm/-0.7 SD).
In the Turkish girl SR6882 (Figure 3,B) a heterozygous de-novo ~ 5.4 Mb deletion in 15q26 
was detected. The imbalance affected 26 RefSeq genes among them the IGF1R gene 
8(Figure 2,B). FISH analyses of  parental samples revealed a normal karyotype without 
balanced rearrangements involving the deleted region. The patients´ conventional 
cytogenetic karyotype was normal. The girl was born at 42 weeks. Postnatal growth was 
restricted and at the age of 3 8/12 years the girl had short stature. No additional SRS 
features were reported, resulting in a low  score of 21.4%. Features not belonging to the SRS 
spectrum were a broad nasal bridge, thick hair, and small hands and feet. Retardation of 
motor or mental skills was not reported but speech was slightly delayed.
The German patient SR8464 (Figure 3,C) was carrier of  a heterozygous de-novo 799 kb 
deletion in 17p13.3 affecting 20 RefSeq genes (Figure 2,C). Conventional karyotyping was 
performed after birth and showed a normal male karyotype. The deletion was confirmed by 
FISH. FISH analyses of the parents revealed a normal karyotype. The patient was born at 
term. Postnatal growth was restricted and the boy had short stature at the age of 2 1/12 
years. In addition to relative macrocephaly, the patient had typical SRS features including a 
triangular face with a prominent forehead, downturned corners of the mouth, and 
retrognathia and therefore fulfilled the SRS criteria (score: 57.1%). Moreover, a long 
philtrum, a high hairline, and small hands and feet were reported. 
We detected nearly the same heterozygous 17p13.3.de-novo deletion in a second patient, 
SR10177 (Figure 2,C). The deletion had a size of  672 kb including 17 RefSeq genes. The 
German boy was born at term. Conventional karyotyping after birth revealed a normal male 
karyotype. At the age of 1 7/12 the boy had short stature and a relative macrocephaly. 
Further features were a triangular shaped face with a prominent forehead and retrognathia 
resulting in a clinical score of 57.1% suggestive for SRS. 
In patient SR1251/06 a heterozygous de-novo 2.5 Mb deletion of the DiGeorge critical region 
in 22q11 was identified (Figure 2,D). The boy was born at term. Growth retardation persisted 
at the age of  7 10/12 years and the patient showed a relative macrocephaly. In addition, the 
triangular face, downturned corners of  the mouth, retrognathia, irregular teeth, ear 
anomalies, and clinodactyly V suggested SRS, but the clinical score (42.8%) did not fit the 
9initial clinical diagnosis of  SRS. Speech delay was reported. No cardiac defects or other 
features typically associated with the 22q11 microdeletion syndrome were present.
In patient SR6820 and her sister SR10737 as well as in their mother a 1 Mb duplication of 
chromosome 22q13.1 including 25 RefSeq genes was identified (Figure 2,E). All three 
carriers of this familial duplication were born at term and had intrauterine and postnatal 
growth restriction. Conventional karyotyping was performed after birth, and revealed a 
normal female karyotype. At an age of  4 5/12 years the girl had several typical SRS features: 
besides persisting short stature and a relative macrocephaly, a triangular shaped face with a 
prominent forehead, retrognathia, clinodactyly V, and body asymmetry were reported (clinical 
score of 85.7%). Growth hormone therapy was started at an age of 4.3 years with a good 
response: her height increased from -4,39 to 1,83 SDS on the first two years of  therapy. Her 
younger sister M10737 was born with a weight of  2480g (-2.35 SD) and a length of 44 cm 
(-3.5 SD). The mother had a birth weight of  2480g (-2.35 SD), a length of 46 cm (-2.59 SD), 
and a head circumference of 32 cm (-2.25 SD score). Further symptoms were not reported.
The female patient SR7705 (Figure 3,D) from Ethiopia carried a large de-novo duplication of 
chromosome Xq25q27 encompassing 9.1 Mb and including 55 RefSeq genes (Figure 2,F). 
Conventional karyotyping in the patient and her parents revealed a normal karyotype. 
Microsatellite typing showed that the paternal chromosome was affected, X inactivation 
studies did not indicate that the affected X chromosome was silenced. Birth measures were 
not available. At about 3 years of  age, the girl had short stature and relative macrocephaly. 
Further features suggestive of  SRS were a triangular shaped face with a prominent forehead 
and asymmetry of the body and the limbs (clinical score: 63.6%). The girl had a broad nasal 
bridge, thick hair, and a single palmar crease of  both hands. Additionally, a mild mental 
retardation was reported.
CNVs of unknown significance
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In 5 patients, CNVs were classified as of unknown significance because a phenotypic effect 
was not obvious. In case of patient SR4178, carrying a 1q21 deletion affecting the TAR 
locus, we assume that the SRS phenotype and the TAR deletion without clinical outcome are 
coincidental findings, however a pathophysiological significance can not be excluded. The 
variants in 15q21 ( SR398/07) and 16q24 (SR596/07) have not yet been reported. Only 
patients with larger/overlapping imbalances affecting these regions have been described but 
they did not show phenotypes corresponding to SRS.
In two patients (SR6415, SR9937), the evaluation of the familial 16p13 microduplication was 
challenging because it overlapped with the recently described 16p13 microduplication/
microdeletion syndromes. However, the microduplication 16p13 has been rather classified as 
a benign variant in the population14.
To find out whether there is a relationship between the total CNV burden and the clinical 
severity scores of our patients, we additionally compared the total CNV count in the patient 
subgroup with a low  clinical score not suggestive for SRS and in the patient subgroup with a 
more typical SRS phenotype. The average CNV count in the low  score group was 7.7 while 
in the high score group we found 8.1 CNVs on average. Furthermore, we compared the 
mean clinical severity scores of patients with pathogenic CNVs, CNVs of unknown 
significance, and apathogenic CNVs that were 53.4 %, 45.2 % and 46.5 % respectively.
In addition, the samples of the 41 patients were screened for regions of homozygosity 
suggestive of mitotic recombination events reminiscent of uniparental disomy. No patients 
with uniparental disomy could be identified.
Discussion
As a uniform and standardised classification system for SRS is lacking, and the clinical 
spectrum comprises many unspecific features overlapping with other congenital disorders, 
our cohort consists of a clinically as well as genetically heterogeneous group. Indeed, we 
have to consider that a significant fraction of our patients was referred with the clinical 
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diagnosis of  SRS but showed only slight compatible features. To compare these 
heterogeneous phenotypes of  our patients we therefore applied the clinical scoring system 
recently developed by Bartholdi et al.2 (Table II). The broad range of the score reflected the 
clinical heterogeneity in our idiopathic SRS patients (21.4-85.7%), and thereby indirectly 
corresponds to the heterogeneous pattern of genomic imbalances in this cohort. As expected 
from previous studies reporting on a more typical SRS phenotype in 11p15 hypomethylation 
carriers in comparison to upd(7)mat patients and probands with unknown molecular 
defects2,3,5,15, our cohort of idiopathic patients show  a lower median clinical score (47.1%) 
than ICR1 hypomethylation carriers with a mean score of 71.8%. 
Among the patients carrying pathogenic CNVs, four children showed a clinical score of  more 
than 53.3% corresponding to a characteristic SRS phenotype, i.e. the carriers of the 
deletions in 17p13.3 and of the duplications in 22q13 and Xq25q27. In the other four patients 
with pathogenic CNVs, the clinical scores were lower than 53.3% and only slight features of 
SRS were reported. Indeed, the latter aberrations are associated with known microdeletion 
syndromes (1q21, 15q26, 22q11), and our findings rather reflect the unspecificity of clinical 
features overlapping between SRS and the detected syndromes. 
The distal 1q21 microdeletion which we detected twice (SR5695, SR9116) is associated with 
a quite variable phenotype including short stature (in 47.6% of carriers), a mild to moderate 
developmental delay, microcephaly, cardiac abnormalities and dysmorphic features13,16. 
Additionally, ADHD and further behavioural abnormalities are observed, and ADHD was 
indeed present in patient SR5695. However, the phenotypic penetrance of the imbalance is 
incomplete, both affected and unaffected carriers have been identified. Haploinsufficiency of 
the CHD1L gene in 1q21 has been suggested as causative for the growth delay in 1q21 
microdeletion patients17. CHD1L is implicated in chromatin remodelling and relaxation as 
well as in DNA damage response18,19 and decatenation. In cell lines carrying the 1q21 
deletion a defect in chromatin remodelling based on impaired decatenation similar to that 
observed in cells from Werner syndrome was documented17. As the only overlapping clinical 
feature in both syndromes was short stature an influence of CHD1L haploinsufficiency on 
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growth was postulated. As a result, we assume that the 1q21 microdeletion in our two 
patients explains their short stature. Their initial clinical diagnosis as SRS was mainly based 
on features reported for both SRS and the 1q21 microdeletion syndrome.
The detection of the 15q26 microdeletion including the IGF1R gene in patient M6882 is 
consistent with data from the literature: Microdeletions affecting IGF1R have been reported 
in 2% of  children born small for gestational age (SGA) with unknown aetiology, intragenic 
deletions and point mutations in IGF1R are present in several growth retarded patients 
presenting a SRS-like phenotype20,21,22. IGF1R is a member of the GH-IGF (growth hormone 
– insulin-like growth factor) cascade and is well-known to be one of the most important 
regulators of prenatal growth. In summary, the 15q26 deletion can be classified as causative 
for the growth retardation in our patient. Indeed, it represents a recurrent pathogenic CNV as 
recently shown by Bruce et al.9 and accounts for a significant number of  growth retarded 
patients with SRS features but not for the typical SRS phenotype.
Overlapping de-novo deletions in 17p13.3 were detected in two patients (M8464 and 
M10177). The deletions did not affect the genes typically affected in Miller-Dieker syndrome 
(MDS), YWHAE and PAFAH1B. The smallest region of  overlap of  both patients spanned 519 
kb and contained 16 RefSeq genes, among them the RPA1 gene which is involved in ATR 
signalling. A causal relationship between haploinsufficiency of factors regulating ATR 
signalling and the growth retardation as well as the microcephaly in MDS patients has been 
postulated23. Patients carrying similar deletions to those identified in our two patients and 
exhibiting intrauterine and postnatal growth retardation were reported by Bruno et al.24 
(patients 5, 6a and 6b). Additionally, in the DECIPHER database several patients with 
overlapping deletions and growth delay are registered. Considering these patient reports and 
the rather similar phenotype of  our two patients (table 2) it is well conceivable that small 
17p13.3 microdeletions are associated with a SRS-like phenotype.
A further CNV associated with growth retardation and further symptoms compatible with SRS 
is a deletion in the DiGeorge (DG) critical region in 22q11. Investigations on the clinical 
features in 78 adults with 22q11-microdeletion25 reported cardiac defects in ~26 % and short 
stature (< 3rd percentile) in ~21 % of patients. Thus, short stature seems to be a common 
observation in 22q11 microdeletion carriers.
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Moreover, we identified a 1 Mb duplication in 22q13.1 in patient M6820 as well as in her 
growth retarded mother and her younger sister who was born small for gestational age, too. 
In the literature, only one growth retarded patient with a similar but larger 22q13 (6.9 Mb) 
duplication has been reported26. 
Patient SR7705 carries a de-novo 9.16 Mb duplication in Xq25q27 affecting 55 RefSeq 
genes. This imbalance was classified as pathogenic due to its size and gene content. 
Neither in the literature nor in the DECIPHER patient database similar patients with clinical 
data are reported. 
In addition to these pathogenic variants, we have to consider those imbalances classified as 
CNVs of unknown significance and the novel 11 benign familial variants in our cohort. It is 
well conceivable that some of  these CNVs turn out to be pathogenic as they either might 
harbour so far unknown factors involved in growth or they represent pathogenic variants of 
incomplete penetrance.
Combining our results with those from the literature9.10, a total cohort of 73 patients with SRS 
features but without 11p15 epimutations and upd(7)mat has meanwhile been analysed for 
submicroscopic imbalances by molecular karyotyping. In 16% of patients (n=12) genomic 
imbalances with an obvious pathogenic effect were identified. In respect to their 
pathophysiological significance for SRS and the clinical scoring, we would define two groups 
of imbalances: (a) (recurrent) pathogenic CNVs, i.e. in 1q21, 15q26, 17p13 and 22q11. All 
these aberrations are known to be associated with known microdeletion syndromes with an 
overlap of  features with SRS. In that context the 12q14 microdeletion syndrome as a further 
entity characterised by features reminiscent of SRS has to be mentioned (for review:27). (b) 
Unique CNVs only reported in single SRS patients but with an obvious influence on the 
phenotype, i.e. in 22q13 and Xq25q27.
This systematic study applied high resolution techniques in growth retarded and dysmorphic 
patients without MR, and our results illustrate the urgent need to apply molecular karyotyping 
in this group of  patients aiming on a satisfactory diagnosis as the basis for an individualised 
14
treatment. Finally, these data allows the identification of genes and genomic regions involved 
in the complex regulation of human growth.
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Table I: Relevant copy number variations detected by molecular karyotyping in growth 
retarded patients with SRS features (# clinical scoring according to Bartholdi et al.2). 
Table II: Clinical overview  and scoring of  the major SRS symptoms in patients with 
ICR1 hypomethylation in 11p15, in idiopathic patients and in 8 carriers of obviously 
pathogenic CNVs. The modified clinical scoring system of Bartholdi et al.2 was applied. (# 
Clinical data of  the ICR1 hypomethylation carriers were ascertained in an ongoing study on 
SRS; * Clinical data were available only from 40 of the 41 idiopathic patients; ND not 
determined; °normal cognitive development was assumed in case abnormalities were not 
reported).
Figure 1: Overall number of  CNVs detected in our cohort of growth retarded patients 
referred as SRS and separation between CNVs with a pathogenic or a benign nature and of 
unknown clinical significance.
Figure 2: Pathogenic copy number changes in patients referred with the clinical 
diagnosis of SRS. Light red bars indicate deletions while green bars indicate duplications. 
Regions affected in known microdeletion syndromes are shown in dark red. Genes probably 
associated with the patients’ phenotype are highlighted in orange. 
Figure 3:  Clinical pictures of children referred as SRS and carrying pathogenic CNVs. a) 
Patient M9116 with a heterozygous 1.65 Mb deletion in 1q21. b) Patient M6882 carrying a 
5.3 Mb deletion in 15q26 at the age of 4 10/12 years. c) Patient M84864 heterozygous for a 
799 kb deletion in 17p13 (left: 1.5 years, right: 3 years). d) The 2 ½ year-old girl M7705 with 
a 9.15 Mb duplication in Xq25q27.  
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